InsiderTrades

Form 4 for GILD Gilead Sciences

Accepted 2024-12-11 00:00:00 ET · period of report 2024-12-10 · accession 0001127602-24-029169 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-12-11 2024-12-10 GILD O'Day Daniel Patrick COB, CEO, Dir M - OptEx — +10.3K 506.3K +2% —
D 2024-12-11 2024-12-10 GILD O'Day Daniel Patrick COB, CEO, Dir F - Tax $92.34 -4,762 501.5K -0.9% -$439.7K
D 2024-12-11 2024-12-10 GILD O'Day Daniel Patrick COB, CEO, Dir M - OptEx — -10.3K 105.0K -9% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-10 M A 10,295 — 506,290 D — — (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2 Common Common Stock 2024-12-10 F D 4,762 $92.34 501,528 D — —
3 Derivative Restricted Stock Unit 2024-12-10 M D 10,295 — 104,977 D — · — to — 10,295 Common Stock (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.